Balaji Amines Q4 FY25 revenue stood at Rs. 393 Cr
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
The pharma market is showing encouraging signs of improvement, positioning us well for future growth
Expect the international business including CDMO business to pick-up in the second half of the financial year
Organization to provide vaccinations & treatments for several monsoon related diseases and illnesses across all 102 clinics
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
The drugmaker's net profit slipped 26 per cent on-year to Rs 143.8 crore
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The revenue for the Q1FY25 came in at Rs 1,085.7 crore, up 16.6 per cent YoY
BAV has revolutionized the animal vaccination industry with its ground-breaking delivery methods that prioritize quality, safety, and efficacy
Subscribe To Our Newsletter & Stay Updated